Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gerard Abidor

Internal Medicine Trumbull, CT Doctor of Osteopathy

NPI 1518014539 CMS profile 576959

145 Pinewood Trl, Trumbull, CT 06611

Open in the dashboard

General payments

$5,038

225 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gerard Abidor of Trumbull, CT is reported in the CMS Open Payments database as having received $5,038 across 225 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,375 73
2024 General $1,360 48
2023 General $936 40
2022 General $342 13
2021 General $172 9
2020 General $208 11
2019 General $645 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gerard Abidor
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Gerard Abidor were reported at $1,375. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Gerard Abidor Internal Medicine median Middle half National median
2019 $645 $159 $48–$570 $163
2020 $208 $119 $33–$402 $114
2021 $172 $135 $37–$521 $132
2022 $342 $141 $42–$496 $149
2023 $936 $149 $45–$519 $160
2024 $1,360 $154 $47–$537 $164
2025 $1,375 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $1,143 59 payments
  2. AstraZeneca Pharmaceuticals LP $886 33 payments
  3. AbbVie, Inc. $676 31 payments
  4. Novo Nordisk Inc $670 32 payments
  5. Abbott Laboratories $370 5 payments
  6. Lilly USA, LLC $220 7 payments
  7. Axsome Therapeutics, Inc. $174 4 payments
  8. Merck Sharp & Dohme Corporation $149 9 payments
  9. Sunovion Pharmaceuticals Inc. $114 10 payments
  10. Ardelyx, Inc. $96 5 payments
  11. Other $540 30 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,033 224 payments
  2. Education $5 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $599 28 payments
  2. FARXIGA $533 14 payments
  3. QULIPTA $425 14 payments
  4. BREZTRI $400 21 payments
  5. TRELEGY ELLIPTA $398 20 payments
  6. FreeStyle Libre 3 $351 4 payments
  7. RYBELSUS $298 15 payments
  8. UBRELVY $217 7 payments
  9. AREXVY $215 8 payments
  10. SHINGRIX $212 13 payments
  11. Other $2,787 150 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 37 drugs

Part D claims

1,112

Median for Internal Medicine: 777

Drug cost

$102,462

Median for Internal Medicine: $73,373

Branded share of claims

21.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 24 $31,248
Januvia Sitagliptin Phosphate Brand 16 $14,608
Tradjenta Linagliptin Brand 13 $12,617
Ozempic Semaglutide Brand 11 $10,349
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 11 $7,272
Breo Ellipta Fluticasone/Vilanterol Brand 12 $4,920
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 31 $4,795
Symbicort Budesonide/Formoterol Fumarate Brand 12 $2,837
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 23 $2,248
Ventolin Hfa Albuterol Sulfate Brand 32 $1,867

The 10 drugs with the highest cost, of 37 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AREXVY
  • GlaxoSmithKline, LLC. $215
$215 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $159
$159 — —
Auvelity
  • Axsome Therapeutics, Inc. $150
$150 — —
QULIPTA
  • AbbVie, Inc. $141
$141 — —
MOUNJARO
  • Lilly USA, LLC $123
$123 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

225 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record